受注:045-509-1970 |
技術サポート:[email protected] 平日9:00〜18:00 1営業日以内にご連絡を差し上げます |
製品コード:A2005 Batch: A200504
Pembrolizumab is a potent, highly selective, fully humanized immunoglobulin (Ig) G4-kappa monoclonal antibody against PD-1 with potential immune checkpoint inhibitory and antineoplastic activities. MW : 146.286 KD.
CAS No. | 1374853-91-4 |
---|---|
Formulation | PBS buffer, pH 7.2 |
Isotype | Human IgG4 |
Source | CHO cells |
Storage (From the date of receipt) |
Store the undiluted solution at 4°C in the dark to avoid freeze-thaw cycles |
Shipping | Shipped under low temperature conditions |
Purity | 98.4% |
Protein concentration | 5.09mg/ml |
Endotoxin Level | ≤1 EU/mg |
Regorafenib plus nivolumab in unresectable hepatocellular carcinoma: the phase 2 RENOBATE trial [ Nat Med, 2024, 10.1038/s41591-024-02824-y] | PubMed: 38374347 |
The BCL-2 inhibitor APG-2575 resets tumor-associated macrophages toward the M1 phenotype, promoting a favorable response to anti-PD-1 therapy via NLRP3 activation [ Cell Mol Immunol, 2024, 21(1):60-79] | PubMed: 38062129 |
Variable PD-1 glycosylation modulates the activity of immune checkpoint inhibitors [ Life Sci Alliance, 2024, 7(3)e202302368] | PubMed: 38176728 |
[ BMC Cancer, 2024, ] | PubMed: 38409035 |
Acquired resistance to CDK4/6 inhibition is associated with dysregulation of multiple pathways including cyclin D-CDK4/6-RB, EGFR/HER, AKT/mTOR and IFN [ Research Square, 2024, 10.21203/rs.3.rs-3782509/v1] | PubMed: none |
A20 promotes colorectal cancer immune evasion by upregulating STC1 expression to block "eat-me" signal [ Signal Transduct Target Ther, 2023, 8(1):312] | PubMed: 37607946 |
Circulating extracellular vesicles are monitoring biomarkers of anti-PD1 response and enhancer of tumor progression and immunosuppression in metastatic melanoma [ J Exp Clin Cancer Res, 2023, 42(1):251] | PubMed: 37759291 |
Complement receptor C5aR1 blockade reprograms tumor-associated macrophages and synergizes with anti-PD-1 therapy in gastric cancer [ Int J Cancer, 2023, 153(1):224-237] | PubMed: 36799619 |
Complement receptor C5aR1 blockade reprograms tumor-associated macrophages and synergizes with anti-PD-1 therapy in gastric cancer [ Int J Cancer, 2023, 153(1):224-237] | PubMed: 36799619 |
Expression of PD-1/PD-L1 axis in mediastinal lymph nodes and lung tissue of human and experimental lung fibrosis indicates a potential therapeutic target for idiopathic pulmonary fibrosis [ Respir Res, 2023, 24(1):279] | PubMed: 37964265 |
人間や獣医の診断であるか治療的な使用のためにでない。